Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA ...

Biogen has finalised a $900 million payment to settle a whistleblower lawsuit claiming that it paid kickbacks to US doctors to prescribe its multiple sclerosis drugs.

Biogen has offered to buy all the shares in Sage Therapeutics that it doesn't already own, taking control of their novel antidepressant Zurzuvae. The $7.22-per-share deal for 89.8% of Sage is a 30 ...

Biogen Pharmachem Industries Ltd share price was down by -1.02% from the previous closing price of ₹0.98. Who are peers of Biogen Pharmachem Industries Ltd? The peers of Biogen Pharmachem ...

Leqembi — sold through a partnership between Eisai and Cambridge-based Biogen Inc. — is one of the first medications approved that promises to slow the speed at which Alzheimer’s erases a ...

The P/B ratio shows how a stock's market price compares to its book value. It helps gauge whether a stock is undervalued or overvalued relative to its net assets.

Dividend announcements are not available.